hat
Faktè ki diminye risk gen ladan ormon pou kontwòl nesans, toubal litij, ak bay tete.[5] Apeprè 10% nan ka yo ki gen rapò ak jenetik eritye risk; fanm ak mitasyon nan jèn yo BRCA1 oswa BRCA2 gen sou yon 50% chans pou yo devlope maladi-a.[3] kalite ki pi komen pou kansè nan ovè, comprenant plis pase 95% nan ka yo, se nan ovè malfijyen.[3] Gen senk prensipal subtypes nan ovè malfijyen, nan yo ki -wo klas sewòm malfijyen se pi komen an.[3] Sa yo timè yo te kwè ki kòmanse nan selil ki kouvri ovè yo,[3] menm si gen kèk ka fòm sa a nan tib tronp.[13] Mwens komen ki kalite kansè nan ovè yo gen ladan jèm selil timè ak fè sèks kòd stromal timè.[3] Yon dyagnostik pou kansè nan ovè a se konfime nan yon byopsi nan tisi yo, anjeneral retire li pandan operasyon.[1]
eng
The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age or reach menopause at an older age.[3] Other risk factors include hormone therapy after menopause, fertility medication, and obesity.[4][5] Factors that decrease risk include hormonal birth control, tubal ligation, and breast feeding.[5] About 10% of cases are related to inherited genetic risk; women with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease.[3] The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma.[3] There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common.[3] These tumors are believed to start in the cells covering the ovaries,[3] though some may form at the Fallopian tubes.[13] Less common types of ovarian cancer include germ cell tumors and sex cord stromal tumors.[3] A diagnosis of ovarian cancer is confirmed through a biopsy of tissue, usually removed during surgery.[1]